Email this article ANALYSIS OF SERUM OCTASE CONCENTRATIONS IN PATIENTS WITH PROSTATE CANCER
- Authors: Grigoryev M.E.1, Matveyev V.B.2, Konorev V.A.1, Aksenov A.A.3, Ryzhkov A.D.2
-
Affiliations:
- Department of Urology, Russian State University Medical University, Russian Agency for Health Care
- N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
- Department of Oncology, Russian State Medical University, Russian Agency for Health Care, Moscow
- Issue: Vol 5, No 3 (2009)
- Pages: 52-56
- Section: PROSTATE CANCER
- Published: 30.09.2009
- URL: https://oncourology.abvpress.ru/oncur/article/view/264
- DOI: https://doi.org/10.17650/1726-9776-2009-5-3-52-56
- ID: 264
Cite item
Full Text
Abstract
Objective: to estimate the diagnostic value of octase in patients with prostate cancer (PC) to detect whether they have metastases to the skeleton.
Subjects and methods. To examine the impact of PC on the serum level of octase, the study included 58 PC patients who had received various treatment modalities and 8 control males without PC.
Results. Higher serum octase concentrations in PC patients receiving the maximum androgenic blockade allow one to suspect metastatic progression of a tumor to the skeleton, which necessitates osteoscintigraphy in these patients.
Discussion. The findings lead to the conclusion that octase may be used in the screening of PC patients receiving antiandrogen therapy in order to predict whether there will be bone metastases.
Keywords
About the authors
M. E. Grigoryev
Department of Urology, Russian State University Medical University, Russian Agency for Health Care
Email: vsevolodmatveev@mail.ru
Russian Federation
V. B. Matveyev
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Author for correspondence.
Email: vsevolodmatveev@mail.ru
Russian Federation
V. A. Konorev
Department of Urology, Russian State University Medical University, Russian Agency for Health Care
Email: vsevolodmatveev@mail.ru
Russian Federation
A. A. Aksenov
Department of Oncology, Russian State Medical University, Russian Agency for Health Care, Moscow
Email: vsevolodmatveev@mail.ru
Russian Federation
A. D. Ryzhkov
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Email: vsevolodmatveev@mail.ru
Russian Federation
References
Supplementary files
